Recombinant Human cytomegalovirus Protein TRL14

How is TRL14 protein detected in HCMV virions?

TRL14 can be detected in purified HCMV virions through several complementary approaches:

• Mass spectrometry analysis: Using gel-free two-dimensional capillary liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Fourier transform ion cyclotron resonance (FTICR). This technique identified TRL14 peptides in purified virion samples with a sequence coverage of 7.5% .

• Proteomic workflow:

  • Virus purification through sequential sedimentation and density ultracentrifugation

  • Denaturation of proteins (typically using 8M urea)

  • Tryptic digestion of the denatured proteins

  • Fractionation by cation exchange chromatography

  • LC-MS/MS or FTICR analysis

  • Validation using database search algorithms such as SEQUEST

When analyzing virion composition, high-purity virus preparations are essential as cellular contaminants can confound results. Electron microscopy validation of virus preparations is recommended before proteomic analysis .

What is the immunological significance of TRL14 in HCMV infection?

TRL14 represents one of the most significant HCMV antigens recognized by the human immune system, particularly by CD4+ T cells. Key findings include:

• TRL14 is among the 10 most frequently recognized antigens by CD4+ T cells during HCMV infection

• While gB-specific CD4+ T cell responses are most frequently detected in healthy individuals (>30%), some individuals (<5%) show higher numbers of precursors specific for TRL14

• The strong CD4+ T cell response to TRL14 suggests its potential utility in vaccine development and immunotherapeutic approaches

Methodologically, TRL14-specific T cell responses can be measured using:

• FluoroSpot or ELISPOT assays with TRL14 peptide pools

• Intracellular cytokine staining following peptide stimulation

• MHC class II tetramer analysis for specific epitopes

Researchers should consider measuring both IFN-γ and IL-10 responses to gain a complete picture of the functional T cell response .

How is recombinant TRL14 protein expressed and purified for research applications?

Recombinant TRL14 is typically expressed in E. coli expression systems with an N-terminal His tag to facilitate purification. The expression and purification workflow includes:

• Expression system: E. coli is the most common host for TRL14 expression

• Vector construction: The TRL14 gene (1-186aa) is cloned into an expression vector with a His tag

• Induction conditions: Optimized temperature, IPTG concentration, and induction time

• Purification: Affinity chromatography using Ni-NTA or similar matrices

• Quality control: SDS-PAGE to confirm purity (>90% purity is typically achieved)

Final preparation is often supplied as a lyophilized powder for extended shelf stability. For reconstitution, researchers should use deionized sterile water to a concentration of 0.1-1.0 mg/mL, with 5-50% glycerol recommended for long-term storage .

What are the optimal storage conditions for recombinant TRL14 protein?

To maintain the biological activity and stability of recombinant TRL14 protein, the following storage conditions are recommended:

• Long-term storage: Store lyophilized protein at -20°C to -80°C

• Reconstituted protein: Store at 4°C for up to one week

• Aliquoting: For multiple use, divide into small aliquots to avoid repeated freeze-thaw cycles

• Buffer composition: Tris/PBS-based buffer with 6% trehalose at pH 8.0 is optimal for lyophilized storage

• Glycerol addition: Add glycerol to a final concentration of 50% for reconstituted protein stored at -20°C

Experimental data indicates that repeated freeze-thaw cycles significantly decrease protein activity, making proper aliquoting essential for maintaining protein functionality across multiple experiments .

What experimental techniques are suitable for studying TRL14 function?

Several approaches can be employed to investigate TRL14 function:

• Protein-protein interaction studies:

  • Co-immunoprecipitation assays

  • Yeast two-hybrid screening

  • Proximity labeling techniques (BioID or APEX)

  • Pull-down assays using His-tagged recombinant TRL14

• Cellular localization studies:

  • Immunofluorescence microscopy with anti-TRL14 antibodies

  • Subcellular fractionation followed by Western blotting

  • Live-cell imaging with fluorescently tagged TRL14

• Functional assays:

  • T cell activation assays using TRL14 peptides or recombinant protein

  • Viral growth curve analysis in cells overexpressing or depleted of TRL14

  • Chromatin immunoprecipitation for detecting potential interactions with host chromatin

• Structural analysis:

  • Crystallography or cryo-EM for tertiary structure determination

  • Circular dichroism for secondary structure analysis

  • HDX-MS for conformational dynamics

These approaches can be used individually or in combination to gain comprehensive insights into TRL14 function in the context of HCMV infection .

How can researchers analyze the TRL14-specific T cell response in HCMV infection?

Analysis of TRL14-specific T cell responses requires methodological rigor. The recommended workflow includes:

• Sample preparation:

  • Isolation of peripheral blood mononuclear cells (PBMCs) from HCMV-seropositive donors

  • Enrichment of CD4+ T cells using magnetic separation if needed

• Stimulation conditions:

  • Use overlapping peptide pools spanning the entire TRL14 sequence

  • Include appropriate positive controls (e.g., PHA, SEB) and negative controls

  • Typical incubation period: 16-18 hours for ELISPOT/FluoroSpot assays

• Detection methods:

  • FluoroSpot assay for simultaneous detection of multiple cytokines (e.g., IFN-γ and IL-10)

  • Flow cytometry for phenotypic characterization (CD45RA, CD27, CCR7 expression)

  • Intracellular cytokine staining for functional analyses

• Data analysis:

  • Define positive response threshold (e.g., >100 spot-forming units/million cells)

  • Compare responses across different age groups and donors

  • Correlate with viral control in clinical settings if applicable

Studies have shown that TRL14-specific responses persist throughout the lifespan of HCMV-seropositive individuals, without significant expansion with increasing age, in contrast to some other HCMV antigens .

What is the role of TRL14 in HCMV virion structure and function?

TRL14 has been identified as a glycoprotein component of the HCMV virion, with several important structural and functional implications:

• Virion localization: Proteomics studies have categorized TRL14 as a virion glycoprotein, suggesting it may be present on the virion envelope or tegument

• Abundance in virions: Quantitative proteomics indicates that TRL14 is present in lower abundance compared to major structural proteins like pp65 (UL83), but is consistently detected in purified virion preparations

• Differential presence: Interestingly, TRL14 was detected in HCMV virions but not in dense bodies (virus-like particles lacking capsids and viral DNA), suggesting a potential role specific to infectious particles

• Functional significance: While the exact function remains to be fully elucidated, its consistent presence in virions across different HCMV strains suggests an important role in the viral life cycle

Research approaches to further investigate TRL14's role in virion structure include immuno-electron microscopy, virion fractionation studies, and creation of TRL14-deleted recombinant viruses to assess impacts on viral assembly and infectivity .

What is known about TRL14's role in HCMV latency and reactivation?

The role of TRL14 in HCMV latency and reactivation is an active area of research. Current understanding includes:

• Expression during latency: Studies using next-generation sequencing approaches have analyzed the transcriptome of latently infected CD14+ and CD34+ cells. While some viral transcripts have been identified during latency (such as RNA4.9, RNA2.7, UL84, and UL44), TRL14 transcription during latency remains less characterized .

• Potential immune evasion functions: TRL14's strong immunogenicity suggests it may play a role during reactivation phases. Some viral proteins with high immunogenicity also possess immune evasion functions to counterbalance host recognition.

• Research approaches for latency studies:

  • Chromatin immunoprecipitation (ChIP) followed by next-generation sequencing to identify protein-DNA interactions during latency

  • RNA-seq of latently infected cells to detect potential TRL14 transcription

  • FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements) analysis to identify nucleosome-depleted viral DNA regions that may regulate TRL14 expression

  • In vitro latency models using CD14+ monocytes or CD34+ cells

Researchers investigating TRL14's role in latency should consider both experimental and natural latency settings to validate findings .

How does TRL14 compare to other immunodominant HCMV proteins in research applications?

TRL14 represents one of several immunodominant HCMV proteins recognized by CD4+ T cells. Comparative analysis with other HCMV proteins reveals:

For research applications:

• TRL14 may be particularly valuable for studying CD4+ T cell responses in specific individuals with strong TRL14 recognition

• When developing comprehensive immune monitoring assays, inclusion of TRL14 alongside more universally recognized antigens like pp65 and gB is recommended

• For vaccine development, TRL14 might represent a complementary antigen to include for broader population coverage

What methodological considerations are important when using recombinant TRL14 for structure-function studies?

When conducting structure-function studies with recombinant TRL14, researchers should consider:

• Protein folding verification:

  • Circular dichroism (CD) spectroscopy to assess secondary structure

  • Limited proteolysis to evaluate conformational integrity

  • Size exclusion chromatography to detect aggregation

• Post-translational modifications:

  • E. coli-expressed TRL14 will lack mammalian glycosylation patterns

  • For studies requiring glycosylated TRL14, consider mammalian or insect cell expression systems

  • Evaluate the impact of His-tag on protein function; consider tag removal for certain applications

• Functional domain mapping:

  • Generate truncation mutants to identify functional domains

  • Site-directed mutagenesis of conserved residues

  • Chimeric proteins with related viral proteins to determine specificity

• Biophysical characterization:

  • Differential scanning fluorimetry to assess thermal stability

  • Surface plasmon resonance for interaction kinetics

  • Hydrogen-deuterium exchange mass spectrometry for conformational dynamics

• Experimental controls:

  • Include inactivated/denatured TRL14 as negative control

  • Use related viral proteins as specificity controls

  • Validate findings across multiple experimental systems

These methodological considerations will help ensure robust and reproducible findings in structure-function studies of TRL14 .

How can researchers investigate TRL14's interaction with the host immune system?

To investigate TRL14's interactions with the host immune system, consider these methodological approaches:

• T cell epitope mapping:

  • Overlapping peptide libraries spanning TRL14 sequence

  • ELISPOT or intracellular cytokine staining to identify stimulatory peptides

  • HLA restriction analysis using blocking antibodies or matched/mismatched APCs

  • Confirmation with synthesized minimal epitopes

• Antigen presentation studies:

  • Pulse dendritic cells with recombinant TRL14 and co-culture with T cells

  • Track intracellular processing using fluorescently labeled TRL14

  • Inhibit specific processing pathways to determine processing requirements

• Functional consequences of T cell recognition:

  • Cytokine profiling (both Th1 and Th2 cytokines)

  • Cytotoxicity assays against TRL14-expressing targets

  • Proliferation assays to assess T cell expansion

• In vitro viral control models:

  • Co-culture TRL14-specific T cells with infected cells

  • Measure viral dissemination using reporter viruses

  • Compare effectiveness of TRL14-specific T cells with T cells targeting other viral antigens

Research has shown that CD4+ T cells specific to HCMV proteins can directly control viral replication through both cytotoxic and cytokine-mediated mechanisms, suggesting TRL14-specific T cells may similarly contribute to viral control .

What are the latest research developments regarding TRL14's role in HCMV pathogenesis?

Recent research developments regarding TRL14's role in HCMV pathogenesis include:

• Immune recognition patterns:

  • TRL14 has been identified as one of the 10 most frequently recognized HCMV antigens by CD4+ T cells

  • Unlike some HCMV-specific T cell responses that accumulate with age, TRL14-specific responses appear to be maintained without significant expansion in older donors

  • TRL14 recognition shows individual variation, with high precursor frequencies in a subset of donors

• Virion incorporation:

  • Comprehensive virion proteomics has confirmed TRL14 as a component of infectious virions but not dense bodies

  • Its classification as a glycoprotein suggests potential roles in virion structure or host cell interactions

• Research limitations and future directions:

  • A comprehensive understanding of TRL14's specific function remains elusive

  • Further studies utilizing targeted mutagenesis, structure determination, and in vivo models are needed

  • Integration of TRL14 findings with broader HCMV immunobiology may reveal its significance in pathogenesis

Future research should focus on determining TRL14's precise function in viral replication, potential immune evasion activities, and its contribution to viral pathogenesis in different host tissues .